Trulicity (Dulaglutide) in Adults 65 and Older: Off-Label Use, Safety, and Clinical Guidance

What Does FDA Approval Actually Cover for Older Adults?

Dulaglutide carries two FDA-approved indications: glycemic control in adults with type 2 diabetes mellitus, and reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Neither indication contains an upper age limit. The label does note that clinical studies enrolled patients as old as 91, though the subgroup sizes above age 75 are small.

The FDA prescribing information states: "No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical and post-marketing experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."

That caveat about "greater sensitivity" is the clinical starting point for every geriatric prescribing decision.

What the Labeling Does Not Address

The label does not address weight management, nephroprotection, or neurocognitive risk reduction in older adults. Prescribers who use dulaglutide for those purposes in patients 65 and older are doing so off-label, which is legal and sometimes evidence-supported, but requires informed consent documentation and a documented clinical rationale.

Age-Related Pharmacokinetic Changes

A population pharmacokinetic analysis published in Clinical Pharmacokinetics found that age did not significantly alter dulaglutide exposure after accounting for body weight and renal function [1]. Clearance is primarily non-renal, which is clinically convenient in a population where creatinine-based estimates frequently underestimate true glomerular filtration rate. Nonetheless, reduced gastric motility common in older adults may amplify nausea and vomiting, particularly during the first four to eight weeks of therapy.

Off-Label Uses in Adults 65 and Older

Weight Management Without Diabetes

Obesity in adults 65 and older is not simply a metabolic number. Excess adiposity at this age is linked to functional decline, osteoarthritis, sleep-disordered breathing, and increased surgical risk. The GLP-1 receptor agonist semaglutide 2.4 mg (Wegovy) holds FDA approval for chronic weight management regardless of diabetes status, but dulaglutide does not. Prescribers who choose dulaglutide for weight loss in non-diabetic older adults are prescribing off-label.

The AWARD-11 trial (N=1,842) demonstrated that dulaglutide 4.5 mg produced a mean body weight reduction of approximately 10.4 kg from baseline over 36 weeks in adults with type 2 diabetes, compared with 2.7 kg for the 0.75 mg dose [2]. No trial has prospectively examined the 4.5 mg dose exclusively in non-diabetic adults aged 65 and older, which is a genuine evidence gap.

One key concern is the composition of weight lost. Data from GLP-1 agonist trials across drug classes consistently show that roughly 25 to 40 percent of total weight lost comes from lean mass rather than fat mass alone [3]. In an older adult who may already have reduced skeletal muscle mass, losing an additional several kilograms of lean tissue can cross a threshold into clinically significant sarcopenia. Resistance exercise during GLP-1 therapy is not optional in this population.

Nephroprotection in CKD

The AWARD-7 trial (N=577) compared dulaglutide 1.5 mg and 0.75 mg weekly against insulin glargine in patients with type 2 diabetes and moderate-to-severe CKD (eGFR 15 to 59 mL/min/1.73 m²) over 52 weeks [4]. Dulaglutide at 1.5 mg attenuated eGFR decline by approximately 1.5 mL/min/1.73 m² compared with insulin glargine, a statistically significant difference (P<0.05). A meaningful proportion of that cohort was older than 60. This data supports off-label nephroprotective use in older adults with CKD, though it does not meet the evidentiary bar of a dedicated outcomes trial in the geriatric population specifically.

Possible Dementia-Risk Attenuation

This is the most speculative off-label use. Observational data published in JAMA Neurology in 2024 suggested that GLP-1 receptor agonist users with type 2 diabetes had a 33% lower incidence of Alzheimer's disease diagnosis over a median follow-up of 3.7 years compared with matched non-users [5]. The mechanism is thought to involve insulin signaling in the brain, neuroinflammation reduction, and improved cerebrovascular perfusion secondary to better glycemic and blood-pressure control.

Dulaglutide has not been tested in a prospective randomized trial for dementia prevention. The ongoing EVOKE trial is examining semaglutide for this purpose, and its results may inform extrapolation to dulaglutide. Until that evidence matures, dementia-risk attenuation is a hypothesis, not an indication.

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Non-alcoholic steatohepatitis, now reclassified as MASH, is more prevalent in older adults with visceral obesity. Small trials with GLP-1 agonists show liver-fat reduction and histologic improvement. Resmetirom (Rezdiffra) became the first FDA-approved MASH treatment in March 2024, but dulaglutide is sometimes used off-label in MASH patients who also carry type 2 diabetes. Evidence specific to the geriatric population remains limited to case series and post-hoc subgroup analyses.

Cardiovascular Outcomes Data in Older Adults

The REWIND trial (N=9,901) is the foundational cardiovascular outcomes trial for dulaglutide [6]. It enrolled patients with type 2 diabetes aged 50 and older with either established cardiovascular disease or cardiovascular risk factors, and it followed them for a median of 5.4 years. The mean age at enrollment was 66.4 years, making REWIND the GLP-1 cardiovascular outcomes trial with the oldest mean enrollment age at the time of publication.

Dulaglutide reduced the primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) by 12% relative to placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99, P<0.026). In a pre-specified subgroup analysis, the benefit appeared consistent across age strata, including patients 65 and older, though subgroup confidence intervals were wider [6].

Stroke Reduction Signal

The REWIND data showed a particularly notable reduction in non-fatal stroke, with a hazard ratio of 0.76 (95% CI 0.61 to 0.95). Stroke is the cardiovascular event with the highest long-term disability burden in older adults, so this signal holds particular clinical weight for the geriatric prescriber.

Heart Failure: Neutral Evidence

Unlike sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dulaglutide has not demonstrated a significant reduction in heart failure hospitalizations. The REWIND trial was not powered for that endpoint. Older adults with heart failure with reduced ejection fraction should likely have an SGLT-2 inhibitor as part of their regimen, with dulaglutide considered additive rather than substitutive for heart-failure-specific risk reduction.

Dosing Strategy for Patients Aged 65 and Older

The HealthRX geriatric GLP-1 titration framework for dulaglutide uses a slower-than-label escalation schedule to reduce nausea-driven volume depletion and functional decline:

Phase 1 (Weeks 1 to 8): 0.75 mg subcutaneously once weekly. Evaluate gastrointestinal tolerance, hydration status, and renal function at week 4.

Phase 2 (Weeks 9 to 16): Increase to 1.5 mg only if the patient tolerates Phase 1 without significant GI symptoms (defined as less than two nausea or vomiting episodes per week) and eGFR is stable within 15% of baseline.

Phase 3 (Weeks 17 onward): Consider 3.0 mg if additional glycemic or weight benefit is needed, weight-bearing exercise is ongoing, and albumin or DEXA-confirmed lean mass has not declined more than 2% from baseline.

Phase 4 (Optional): The 4.5 mg dose is reserved for patients who demonstrate clear clinical benefit at 3.0 mg without functional deterioration and who have documented informed consent for off-label dosing if the indication is weight management in a non-diabetic patient.

This four-phase approach is not found in any published guideline. It represents the HealthRX medical team's synthesis of REWIND subgroup data, AWARD-7 safety findings, and American Geriatrics Society Beers Criteria principles regarding medications with high nausea potential in older adults.

Monitoring Parameters

Clinicians should check the following at each visit during titration:

• Body weight and waist circumference
• Hand-grip strength or 30-second chair stand test as a sarcopenia screen
• Serum creatinine and eGFR
• Blood pressure (volume depletion from nausea may cause orthostatic hypotension)
• HbA1c if treating diabetes; fasting glucose if treating off-label

The American Geriatrics Society recommends that HbA1c targets in older adults be individualized, ranging from less than 7.5% for healthy older adults to less than 8.5% for those with significant comorbidities or limited life expectancy [7].

Safety Profile: Risks Amplified by Aging

Gastrointestinal Adverse Effects

Nausea, vomiting, and diarrhea occur in 12 to 21% of dulaglutide users across key trials [2]. In older adults, these effects carry additional consequence. A single episode of significant vomiting in a frail 78-year-old can produce 1.5 to 2 liters of fluid loss, sufficient to cause acute prerenal azotemia or orthostatic syncope. Clinicians should counsel patients explicitly to maintain oral hydration during the first eight weeks and to hold the medication and seek care if they cannot keep fluids down for more than 24 hours.

Hypoglycemia Risk

As monotherapy, dulaglutide carries a low hypoglycemia risk because it stimulates insulin secretion in a glucose-dependent manner. The risk rises substantially when combined with sulfonylureas or insulin. In the AWARD-2 trial, 40% of patients on dulaglutide plus glimepiride experienced at least one hypoglycemic episode, compared with 11% on dulaglutide alone [8]. Sulfonylurea dose reduction at the time of dulaglutide initiation is standard practice, and it matters more in elderly patients where hypoglycemia-associated falls carry greater fracture and mortality risk.

Pancreatitis and Thyroid C-Cell Risk

The prescribing information carries a boxed warning for thyroid C-cell tumors based on rodent data. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. These contraindications apply regardless of age, but older adults with a longer oncologic history may require more careful review.

Acute pancreatitis has been reported with GLP-1 agonists. Older adults with a history of gallstone disease, hypertriglyceridemia, or alcohol use should be counseled on abdominal warning symptoms.

Gastroparesis

Pre-existing diabetic gastroparesis is a relative contraindication to GLP-1 receptor agonists. GLP-1 receptors slow gastric emptying by design. In a patient who already has delayed gastric emptying, adding a GLP-1 agonist can worsen symptoms significantly and impair oral medication absorption, including oral hypoglycemics, anticoagulants, and antiepileptics. Older adults with longstanding diabetes have higher rates of subclinical gastroparesis, making a thorough GI history essential before prescribing.

Bone and Muscle Considerations

Body weight reduction from any mechanism reduces mechanical loading on bone. In older adults, lower mechanical load can reduce bone mineral density. A post-hoc analysis of REWIND did not show a significant increase in fracture risk with dulaglutide, but the trial was not powered for this outcome and follow-up was 5.4 years, possibly insufficient to detect modest BMD changes [6]. Clinicians prescribing dulaglutide for weight loss in adults 65 and older should have a baseline DEXA scan on file and ensure adequate calcium (1,200 mg daily) and vitamin D (800 to 1,000 IU daily) intake per National Osteoporosis Foundation guidance.

Drug Interactions Relevant to Geriatric Polypharmacy

Older adults take an average of five or more prescription medications. Three interaction patterns deserve specific attention with dulaglutide:

Oral medications with narrow therapeutic windows. Because GLP-1 agonists slow gastric emptying, the time to peak concentration (Tmax) of orally administered drugs may shift. Warfarin INR should be monitored more frequently in the first 8 weeks after dulaglutide initiation. Levothyroxine absorption may be mildly reduced; TSH should be checked at 6 weeks.

Diuretics and ACE inhibitors. Volume depletion from nausea combined with loop diuretic therapy can precipitate acute kidney injury. Consider holding or reducing diuretic doses during the GI adjustment period, particularly in patients with baseline eGFR <45 mL/min/1.73 m².

Sulfonylureas and insulin. As noted above, dose reduction is standard at initiation. The ADA Standards of Care in Diabetes 2024 recommend reducing sulfonylurea dose by 25 to 50% when adding any GLP-1 receptor agonist [9].

Practical Administration Considerations for Older Adults

Dulaglutide is supplied as a single-dose autoinjector pen (0.75 mg/0.5 mL and 1.5 mg/0.5 mL; higher doses in larger-volume pens). The device requires no mixing, no needle attachment, and no dose dialing. For patients with arthritis, reduced hand strength, or visual impairment, this design offers a meaningful practical advantage over insulin vials or devices requiring manual dose setting.

Refrigerated storage is required (36 to 46 degrees Fahrenheit), but the pen can be kept at room temperature (below 86 degrees Fahrenheit) for up to 14 days. Cognitively intact patients managing their own medications should receive written instructions on storage, as accidental room-temperature storage beyond 14 days is a common cause of reduced drug efficacy.

Injection sites include the abdomen, upper arm, or thigh. Rotating sites is standard practice. In thin older adults with reduced subcutaneous fat, the abdomen typically provides the most reliable absorption surface.

When to Avoid or Discontinue Dulaglutide in Elderly Patients

Stop or do not start dulaglutide if any of the following apply:

• Personal or family history of medullary thyroid carcinoma or MEN2
• Active or recent acute pancreatitis
• Severe gastroparesis (documented by gastric emptying study)
• eGFR <15 mL/min/1.73 m² (very limited safety data; severe CKD)
• Active decompensated heart failure with severe volume depletion
• Patient cannot maintain oral hydration and has no caregiver support to monitor for dehydration

Functional status matters as much as biochemical parameters. A patient scoring 3 or lower on the Clinical Frailty Scale may tolerate dulaglutide, but a patient scoring 6 or 7 (moderately to severely frail) who lacks appetite and is already at nutritional risk deserves a very careful risk-benefit conversation before any anorexigenic medication is started.

What Current Guidelines Say About GLP-1 Agonists in Older Adults

The ADA Standards of Care in Diabetes 2024 recommend GLP-1 receptor agonists as preferred agents for adults with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of age, provided tolerability is acceptable [9]. The Endocrine Society Clinical Practice Guideline on Diabetes in Older Adults (2019) states that drug selection in older adults should prioritize agents with low hypoglycemia risk and cardiovascular benefit, categories that include GLP-1 receptor agonists [10].

Neither guideline provides a specific dulaglutide dose recommendation for adults older than 75. The REWIND trial enrolled patients up to 91 years old, but fewer than 5% of the total cohort was older than 80, limiting statistical confidence in that subgroup.

The American Geriatrics Society Beers Criteria 2023 does not list GLP-1 receptor agonists as medications to avoid in older adults, though it notes the need for careful monitoring of GI adverse effects and nutritional status [11].